{
    "nctId": "NCT02628613",
    "briefTitle": "Neoadjuvant Paclitaxel Plus Epirubicin Versus Vinorelbine Plus Epirubicin in Breast Cancer With TEKT4 Variations",
    "officialTitle": "Phase II Randomized Clinical Trial and Biomarker Analysis of Paclitaxel Plus Epirubicin Versus Vinorelbine Plus Epirubicin as Neoadjuvant Chemotherapy in Locally Advanced HER2-Negative Breast Cancer With TEKT4 Variations",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 91,
    "primaryOutcomeMeasure": "pathologic Complete Response (pCR)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Age: 18-70 years old\n2. Expected survival \\> 12 months\n3. Baseline ECOG Performance Status rating 0-1\n4. Na\u00efve to chemotherapy or hormonal treatments\n5. Radiologically confirmed and biopsy diagnosed invasive ductal carcinoma of breast and prepared to be treated surgically\n6. Locally advance breast cancer of stage IIb-IIIc\n7. HER-2 negative confirmed by immunohistochemistry, Ki-67\u226520%\n8. TEKT4 variation confirmed by DNA sequencing\n9. No concurrent malignancy (except controlled cervical carcinoma in situ or basal cell carcinoma of skin)\n10. Patients have measurable lesions (according to RECIST v1.1 criteria)\n11. Intention to cooperate with baseline puncture and neoadjuvant therapy\n12. No advanced metastasis or metastasis involving brain or liver\n13. Adequate bone marrow function, blood routine examination shows neutrophil count \u2265 1.5x109/L, hemoglobin level \u2265 100 g/L, Platelets \u2265 100 x 109/L\n14. Adequate liver and kidney function, serum aminotransferase (AST) \u2264 60U/L, serum total bilirubin \u2264 2.5 times ULN, serum creatinine \u2264110\u03bcmol/L, urea nitrogen \u22647.1mmol/L\n15. No coagulation abnormality\n16. Normal heart function, with normal ECG and LVEF \u2265 55%\n17. Women of childbearing age agree to take reliable contraceptive measures during clinical trials, and negative serum or urine pregnancy test within 7 days prior to administration\n18. No coagulation abnormality\n19. Sign the informed consent statement and voluntarily receive follow-ups, treatments, laboratory tests and other research procedures according to protocol.\n\nExclusion Criteria:\n\n1. Previous regional or systemic treatment for breast cancer (include but not limited to chemotherapy, radiotherapy, targeted therapy, other clinical trials)\n2. Inflammatory breast cancer, bilateral breast cancer or breast cancer already with distant metastasis\n3. Complicated with uncontrolled lung disease, severe infection, active peptic ulcer, blood clotting disorders, severe uncontrolled diabetes, connective tissue disorders or bone marrow suppression, and intolerance to neoadjuvant therapy or related treatment\n4. Peripheral neuropathy \\>1 degree caused by any reason\n5. History of congestive heart failure, uncontrolled or symptomatic angina, arrhythmias or history of myocardial infarction, refractory hypertension (systolic blood pressure \\> 180 mmHg or diastolic blood pressure \\> 100 mmHg);\n6. Breast cancer during lactation or pregnancy\n7. Unwillingly to receive baseline puncture or neoadjuvant therapy\n8. Mental illness or incompliance to treatment caused by other reasons\n9. Known history of severe hypersusceptibility to any agents used in the treatment protocol\n10. Patients received major surgery or suffered from severe trauma within 2 months of first administration\n11. Currently enroll or recently used (30 days within enrollment) other agent under research or involved in other trial\n12. Known to be infected with human immunodeficiency virus (HIV)\n13. Other circumstances considered to be inappropriate to be enrolled by researchers",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}